ReviewLife (Basel, Switzerland)2026
C-Reactive Protein in Saliva as a Non-Invasive Marker of Metabolic Syndrome: A Systematic Review and Meta-Analysis.
Review in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS) is a cluster of conditions that rely on low-grade systemic inflammation and increase the risk of cardiovascular disease, type 2 diabetes, and stroke. C-reactive protein (CRP) has attracted growing interest in saliva as a non-invasive alternative to serum CRP testing, though existing evidence remains inconsistent. This systematic review and meta-analysis evaluated the association between salivary CRP levels and MetS and examined the consistency of findings across populations and methodological approaches. PubMed, the Cochrane Library, and Web of Science were searched up to December 2024 following PRISMA 2020 guidelines. Nineteen studies involving 3265 participants with and without MetS were included. Random-effects meta-analysis demonstrated higher salivary CRP levels in individuals with MetS compared with controls (SMD = 1.02; 95% CI -0.23 to 1.81), with substantial heterogeneity (I
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.